Print    Email
Decrease (-) Restore Default Increase (+)

Clinical Trials

Treatment Trial Title Principal Investigator
Allergy and Immunology A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess & compare efficacy & safety of an 8-week treatment with Respimat® inhaler & fluticasone propionate in patients with asthma inadequately controlled on ICS therapy  Jeffrey Leflein, MD 
Allergy and Immunology A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 mg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma  Jeffrey Leflein, MD 
Allergy and Immunology A Phase III, Multicenter, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Response Duration & Safety of Xolair® (Omalizumab) in Patients with Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic  Jeffrey Leflein, MD 
Allergy and Immunology A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy & Safety of Grass (Phleumpratense) Sublingual Tab (SCH 697243) in Subjects Ages 5 to 65 Years w/History of Grass Pollen-Induced Rhinoconjunctivitis  Jeffrey Leflein, MD 
Allergy and Immunology Open-label Patient Continuation of DX-88 (Ecallantide) for acute Hereditary Angioedema (HAE) Attacks  Leflein MD, Jeffrey  
Allergy and Immunology A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess & compare efficacy & safety of an 8-week treatment with Respimat® inhaler & fluticason propionate in patients with asthma inadequately controlled on SABA therapy  Jeffrey Leflein, MD 
Allergy and Immunology A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess & compare efficacy & safety of an 8-week treatment with Respimat® inhaler & fluticasone propionate in patients w/asthma inadequately controlled on med. dose ICS.  Jeffrey Leflein, MD 
Allergy and Immunology A Randomized, Double-Blind, Placebo-Controlled Parallel Group Efficacy & Safety Trial of Sublingual-Oral Immunotherapy (SLIT) in Adults With Allergic Rhinoconjunctivitis Caused by Ragweed Pollen  Jeffrey G. Leflein, M.D. 
A Member of Trinity Health
© 2014 Trinity Health

St. Joseph Mercy Ann Arbor | 5301 McAuley Drive, Ypsilanti, MI 48197 | 734-712-3456